维生素C联合硫胺素治疗脓毒性休克:多中心双盲随机对照研究
ATESS试验为多中心、双盲、随机对照研究,在四个学术急诊科纳入成人脓毒性休克患者111例,治疗组53例接受静脉维生素C(50 mg/kg,单次最大3 g)联合硫胺素(200 mg)每12小时一次共48小时,安慰剂组58例接受等量0.9%氯化钠相同方案。主要终点ΔSOFA评分(入组时SOFA减72小时后SOFA)两组无显著差异(3,IQR -1至5 vs 3,IQR 0至4,p=0.96)。预设次要终点包括休克逆转和28天死亡率亦无显著差异。尽管维生素C和硫胺素水平改善,早期联合治疗未改善脓毒性休克患者的器官功能。
要点
- 多中心双盲RCT纳入111例成人脓毒性休克,治疗组53例、安慰剂组58例。
- 主要终点ΔSOFA评分治疗组3(IQR -1至5)vs 安慰剂组3(IQR 0至4),p=0.96,无显著差异。
- 预设次要终点包括休克逆转和28天死亡率,两组亦无显著差异。
- 治疗组接受静脉维生素C 50 mg/kg(单次最大3 g)联合硫胺素200 mg,每12小时一次共48小时。
- 尽管维生素C和硫胺素水平改善,早期联合治疗未改善器官功能。
适用人群与场景
- 四个学术急诊科收治的成人脓毒性休克患者,于2018年12月至2020年1月入组。
处置流程与药物剂量
- 治疗组:静脉维生素C 50 mg/kg(单次最大剂量3 g)联合硫胺素200 mg,每12小时给药一次,共48小时。
- 安慰剂组:等量0.9%氯化钠,相同给药方案。
研究设计与关键结果
- ATESS试验为多中心、双盲、随机对照研究,1:1随机分组,共纳入111例成人脓毒性休克患者,治疗组53例、安慰剂组58例。
- 主要终点ΔSOFA评分(入组时SOFA减72小时后SOFA):治疗组3(IQR -1至5)vs 安慰剂组3(IQR 0至4),p=0.96,无显著差异。
- 预设的18个次要终点包括休克逆转和28天死亡率,两组间均无显著差异。
- 尽管维生素C和硫胺素水平改善,早期联合治疗未改善器官功能。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于成人脓毒性休克早期患者,静脉维生素C联合硫胺素与安慰剂相比未改善ΔSOFA评分及预设次要终点(包括休克逆转和28天死亡率),不改变现有对该联合方案在脓毒性休克中常规使用的做法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the effects of early combination therapy with intravenous vitamin C and thiamine on recovery from organ failure in patients with septic shock.
METHODS: The ascorbic acid and thiamine effect in septic shock (ATESS) trial was a multi-centre, double-blind, randomized, controlled trial conducted in four academic emergency departments, enrolling adult patients with septic shock from December 2018 through January 2020. Patients were randomly assigned in a 1:1 ratio to either the treatment group [intravenous vitamin C (50 mg/kg, maximum single dose 3 g) and thiamine (200 mg) administration every 12 h for a total of 48 h] or the placebo group (identical volume of 0.9% saline with the same protocol). The primary outcome was Δ Sequential Organ Failure Assessment (SOFA) score (SOFA score at enrolment-SOFA score after 72 h). Eighteen secondary outcomes were predefined, including shock reversal and 28-day mortality.
RESULTS: A total of 111 patients were enrolled, of which 53 were assigned to the treatment group and 58 were assigned to the placebo group. There was no significant difference in ΔSOFA scores between the treatment group and the placebo group [3, interquartile range (IQR) - 1 to 5 vs. 3, IQR 0-4, respectively, p = 0.96]. Predefined secondary outcomes were also not significantly different between the groups.
CONCLUSION: In this study, vitamin C and thiamine administration in the early phase of septic shock did not improve organ function compared with placebo, despite improvements in vitamin C and thiamine levels.
参考来源
- Hwang SY, Ryoo SM, Park JE, et al. Combination therapy of vitamin C and thiamine for septic shock: a multi-centre, double-blinded randomized, controlled study. Intensive Care Med. 2020. PMID: 32780166. doi:10.1007/s00134-020-06191-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。